Judge orders Hegseth to explain US military’s new testosterone policy

What This is

• Defense Secretary Pete Hegseth announced annual testosterone screening for service members age 30 and older, with younger troops able to opt in.
• The plan would offer voluntary testosterone replacement therapy for those found to have low levels, under medical supervision.
• The Pentagon says the screening will be added to routine annual health assessments for active-duty and reserve troops.
• Federal Judge Ana Reyes ordered the government to provide details on the policy’s rationale, costs, and how it would be implemented.
• Reyes raised questions about how testosterone replacement for cisgender troops compares with hormone treatment for transgender men, in a case challenging President Trump’s ban on transgender service members.
• Some coverage says the Pentagon has not clearly explained how the policy applies to women or what thresholds would trigger a “low testosterone” finding.
• Medical experts warn that screening large numbers of healthy, symptom-free people can lead to false positives and unnecessary prescriptions.
• Doctors say testosterone therapy can help some patients with confirmed deficiency, but it often needs repeat testing, close monitoring, and may mean long-term treatment.
• Experts also warn about side effects from testosterone therapy, including fertility problems and risks like blood clots and heart-related issues.
• Some reporting links the Pentagon policy to a broader Trump administration push to make testosterone easier to prescribe, including actions by health agencies and the Food and Drug Administration.

Why This Matters

• It could normalize broad medical screening and medication across the force, even when many people have no symptoms.
• It sharpens the political and moral debate over equal treatment when similar hormones are encouraged for some troops but used to bar others.
• Because military careers hinge on medical status, “voluntary” treatment can still feel pressured and may affect assignments and evaluations.
• If the program scales, it could drive costs and clinic workload and create long-term follow-up demands for side effects like infertility or blood clots.